HO-1 concentrations 24 hours after cardiac surgery are associated with the incidence of acute kidney injury: a prospective cohort study

Attila Magyar1,2
Martin Wagner2,4
Phillip Thomas1,2
Carolin Malsch2
Reinhard Schneider3
Stefan Störk1,5
Peter U Heuschmann2,4,6
Rainer G Leyh1
Mehmet Oezkur1,2

1Department of Cardiovascular Surgery, University Hospital Würzburg, Germany; 2Institute of Clinical Epidemiology and Biometry, University of Würzburg, Germany; 3Division of Nephrology, Department of Medicine I, University Hospital Würzburg, Germany; 4Comprehensive Heart Failure Center, University of Würzburg, Germany; 5Division of Cardiology, Department of Medicine I, University Hospital Würzburg, Germany; 6Clinical Trial Center Würzburg, University Hospital Würzburg, Germany

Background: Acute kidney injury (AKI) is a serious complication after cardiac surgery that is associated with increased mortality and morbidity. Heme oxygenase-1 (HO-1) is an enzyme synthesized in renal tubular cells as one of the most intense responses to oxidant stress linked with protective, anti-inflammatory properties. Yet, it is unknown if serum HO-1 induction following cardiac surgical procedure involving cardiopulmonary bypass (CPB) is associated with incidence and severity of AKI.

Patients and methods: In the present study, we used data from a prospective cohort study of 150 adult cardiac surgical patients. HO-1 measurements were performed before, immediately after and 24 hours post-CPB. In univariate and multivariate analyses, the association between HO-1 and AKI was investigated.

Results: AKI with an incidence of 23.3% (35 patients) was not associated with an early elevation of HO-1 after CPB in all patients (P=0.88), whereas patients suffering from AKI developed a second burst of HO-1 24 hours after CPB. In patients without AKI, the HO-1 concentrations dropped to baseline values (P=0.031). Furthermore, early HO-1 induction was associated with CPB time (P=0.046), while the ones 24 hours later lost this association (P=0.219).

Conclusion: The association of the second HO-1 burst 24 hours after CPB might help to distinguish between the causality of AKI in patients undergoing CPB, thus helping to adapt patient stratification and management.

Keywords: acute kidney injury, cardiac surgery, heme oxygenase-1, cardiopulmonary bypass

Introduction

Surgery-associated acute kidney injury (AKI) is a common and serious complication after cardiac surgery, which increases the risk of mortality, morbidity as well as length of the hospital stay.1–6 The incidence of AKI associated with cardiac surgery may reach 50%,3,7–10 depending on the definition. The diagnosis of AKI is suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group as an increase in serum creatinine (SCr) and/or a decrease in urine production.11 Even slight elevation of 0.3 mg/dL (AKI stage I) in SCr is considered as an independent predictor of in-hospital, 30-day as well as long-term mortality.12,13 Direct therapy for AKI is limited by the supportive strategy that includes fluid management, adequate drug dosing and dialysis for severe AKI stages.

Early prediction of AKI might allow an interventional therapeutic regime at the intensive care unit (ICU) before the damage of glomerular or renal tubular cells tends to become high grade or even irreversible. Furthermore, early distinction of the stages and causes of AKI might help in decision making in the ICU regarding catecholamine.
therapy, dialysis or fluid/drug management in early postoperative care.

The inducible isoform enzyme heme oxygenase-1 (HO-1) catalyzes the oxidative degradation of heme, producing CO, Fe$^{2+}$ and biliverdin, which is converted to bilirubin by cytosolic biliverdin reductase. HO-1 is upregulated in proximal tubular cells as a response to oxidative stress and has protective anti-inflammatory and anti-oxidant effects.14 HO-1 was first recognized as a rapid and protective response in the context of rhabdomyolysis and heme pigment-induced AKI in animal models.15 The beneficial effects of HO-1 on oxidative stress and prevention of AKI have been reported in multiple animal models.15–17 In one small cohort in cardiac surgery, the association with AKI has been suggested in a clinical setting.18

In this prospective cohort study, we aimed to evaluate the course of HO-1 serum concentration after cardiac surgery and the association with AKI.

**Patients and methods**

**Patient population**

We enrolled in this prospective cohort study 165 patients between April and December 2014. Adult patients undergoing elective cardiac surgical procedure involving cardiopulmonary bypass (CPB) (coronary artery bypass graft [CABG], valve surgery [reconstruction, replacement] or combined CABG and valve surgery; and surgery of the thoracic aorta) were included. Patients signed informed consent form. Patients with chronic kidney disease (CKD) stage 3 or higher, ie, eGFR $<$30 mL/min, with signs of active infection (clinical assessment), women during pregnancy and lactation, as well as patients on COMT inhibitors, MAO inhibitors or on immunosuppression were excluded. Patient enrollment was at least 24 hours prior to surgery. Demography, medical history, medication, details of physical examination, anesthesia details, surgical data and the postoperative data including the hospital discharge were collected by the study personnel and were completed by the Comprehensive Heart Failure Center DataWarehouse.19 The study protocol was approved by the ethics committee at the Medical Faculty of the University of Würzburg (Vote 302/13) and the data protection officer at the University Hospital Würzburg.

**Biomarker measurements**

We collected blood samples at a predefined time schedule (preoperatively; at admission in ICU; 6, 24, and 48 hours after surgery; and at discharge from hospital). These time points were defined by local clinical routine; samples were collected by treating staff, while further processing was performed by study personnel. All samples were processed and stored at $-80^\circ$C. For biomarker analyses, serum samples were thawed at $+4^\circ$C and HO-1 (Enzo LifeSciences, Ann Arbor, MI, USA). Neutrophil gelatinase-associated lipocalin (NGAL; BioPorto Diagnostics A/S, 2900 Hellerup, Denmark) concentrations were measured by ELISA following the manufacturer’s guides. HO-1 was measured at anesthesia induction (baseline), at admission in the ICU and on postoperative day 1 (24 hours postsurgery), while NGAL was measured at baseline and at admission in the ICU.

**Definition of end points and outcomes**

The primary end point of the study was the incidence of AKI within 48 hours after surgery. The severity of postoperative AKI is defined as any of the following: 1. SCr increase by $\geq$0.3 mg/dL within 48 hours; or 2. increase in SCr to $\geq$1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or 3. urine volume $<$0.5 ml/kg/h for 6 hours. The stages of AKI within 48 hours were defined as SCr increase $\geq$0.3 mg/dL or of 1.5–1.99 times baseline as (stage 1), SCr increase of 2.0–2.9× baseline (stage 2) and SCr increase $\geq$3.0 times baseline or SCr $>$4 mg/dL or dialyses (stage 3).

Secondary end points were the length of stay in ICU and hospital, time on mechanical ventilation and in-hospital mortality.

EuroScore II is a mortality risk calculator for cardiac surgical patients considering age, gender, pulmonary disease, extracardiac arteriopathy, neurological status, renal status, cardiac status as well as the complexity of the planned procedure.20 The EuroScore II is therefore a reliable score to rate the preoperative status of the patient. CPB time represents the duration of the operation in which the myocardium suffers from oxidative stress.21 Furthermore, it represents a sound surrogate marker for the course of the operation and is an independent predictor of mortality and morbidity after cardiac surgery.22

**Statistical analyses**

Statistical tests were performed with IBM SPSS 23 Statistics-Software. Continuous variables were described as medians with interquartile range. Categorical variables were presented as numbers and percentages. Normally distributed variables were compared regarding AKI yes/no by $t$-test, parametric variables by Mann–Whitney $U$ test. Fisher’s exact or the chi-squared test was used for categorical values. Correlations were evaluated by Pearson’s rank correlation test. Univariate and adjusted multivariate logistic regression analyses were performed to investigate associations between predictors of development of AKI including clinically relevant variables and renal biomarkers. Variables were included in the multi-
variable analysis using a backward stepwise approach with criteria of \( P < 0.05 \) for inclusion and \( P > 0.10 \) for removal from the model. Areas under the curve of receiver operating characteristic (ROC) were analyzed to assess the cutoff value for postoperative HO-1 levels for predicting AKI. The optimal HO-1 cutoff level was defined as the value that provided the highest sensitivity and specificity for predicting AKI. An explorative, two-sided \( P \)-value of less than 0.05 was considered significant for all results.

**Results**

**Patients’ characteristics**

Of the enrolled 165 patients, 15 were excluded due to withdrawal of consent and change of surgical procedure to off-pump surgery. The patients’ characteristics stratified by development of AKI are displayed in Table 1.

Patients experiencing AKI within 48 hours after surgery were older (70 [65–77] vs 65 [59–75] years, \( P = 0.015 \)) and more likely to report on stroke or transient ischemic attack (TIA) in the medical history (\( P = 0.013 \)). EuroScore II tended to be higher without reaching statistical significance in patients with AKI (1.78 [1.15–3.50] vs 1.63 [0.89–2.77], \( P = 0.055 \)). Moreover, the time on CPB (109 [88–127] vs 110 [66–270], \( P = 0.04 \)) was longer in patients with AKI as compared to those without AKI. Patients with AKI also spent more time on mechanical ventilation (14 [11–23] vs 12 [10–15] hours, \( P = 0.006 \)) and in the ICU (55 [22–96] vs 23 [21–44] hours, \( P = 0.001 \)).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No AKI (n=115)</th>
<th>AKI (n=35)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preoperative</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>33 (28.7)</td>
<td>9 (25.7)</td>
<td>0.83</td>
</tr>
<tr>
<td>Age (years)</td>
<td>65 (59–75)</td>
<td>70 (65–77)</td>
<td><strong>0.015</strong></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>178 (172–180)</td>
<td>167 (161–170)</td>
<td>0.18</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82 (74–90)</td>
<td>81 (75–92)</td>
<td>0.37</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>104 (98–108)</td>
<td>109 (104–116)</td>
<td>0.58</td>
</tr>
<tr>
<td>AMI in medical history, n (%)</td>
<td>25 (21.7)</td>
<td>6 (17.1)</td>
<td>0.64</td>
</tr>
<tr>
<td>Pacemaker/IcD, n (%)</td>
<td>13 (11.3)</td>
<td>3 (8.6)</td>
<td>0.76</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>90 (78.3)</td>
<td>25 (71.4)</td>
<td>0.49</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>24 (20.9)</td>
<td>4 (11.4)</td>
<td>0.32</td>
</tr>
<tr>
<td>Renal impairment, n (%)</td>
<td>7 (6.1)</td>
<td>1 (2.9)</td>
<td>0.68</td>
</tr>
<tr>
<td>COPD, n (%)</td>
<td>5 (4.3)</td>
<td>2 (5.7)</td>
<td>0.66</td>
</tr>
<tr>
<td>Peripheral artery disease, n (%)</td>
<td>32 (27.8)</td>
<td>11 (31.4)</td>
<td>0.67</td>
</tr>
<tr>
<td>EuroScore II</td>
<td>1.63 (0.89–2.77)</td>
<td>1.78 (1.15–3.50)</td>
<td>0.05</td>
</tr>
<tr>
<td>Stroke/TIA, n (%)</td>
<td>6 (5.2)</td>
<td>7 (20.0)</td>
<td><strong>0.013</strong></td>
</tr>
<tr>
<td><strong>Intraoperative</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG, n (%)</td>
<td>67 (58.3)</td>
<td>19 (54.3)</td>
<td>0.7</td>
</tr>
<tr>
<td>Valve surgery, n (%)</td>
<td>61 (53.0)</td>
<td>19 (54.3)</td>
<td>0.999</td>
</tr>
<tr>
<td>CABG/valve in combination, n (%)</td>
<td>12 (10.4)</td>
<td>3 (8.5)</td>
<td>0.999</td>
</tr>
<tr>
<td>Aortic surgery, n (%)</td>
<td>10 (8.7)</td>
<td>5 (14.3)</td>
<td>0.34</td>
</tr>
<tr>
<td>Cardiac re-operation, n (%)</td>
<td>12 (10.4)</td>
<td>3 (8.6)</td>
<td>0.999</td>
</tr>
<tr>
<td>DHCA, n (%)</td>
<td>8 (7.0)</td>
<td>3 (8.6)</td>
<td>0.71</td>
</tr>
<tr>
<td>Operation time (minutes)</td>
<td>229 (193–260)</td>
<td>212 (204–345)</td>
<td><strong>0.013</strong></td>
</tr>
<tr>
<td>CPB time (minutes)</td>
<td>109 (88–127)</td>
<td>110 (66–270)</td>
<td><strong>0.04</strong></td>
</tr>
<tr>
<td><strong>Postoperative</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation (h)</td>
<td>12 (10–15)</td>
<td>14 (11–23)</td>
<td><strong>0.006</strong></td>
</tr>
<tr>
<td>Length of stay in ICU (h)</td>
<td>23 (21–44)</td>
<td>55 (22–96)</td>
<td><strong>0.001</strong></td>
</tr>
<tr>
<td>Resuscitation, n (%)</td>
<td>3 (2.6)</td>
<td>2 (5.7)</td>
<td>0.33</td>
</tr>
<tr>
<td>Mortality, n (%)</td>
<td>0 (0)</td>
<td>5 (14.3)</td>
<td><strong>0.001</strong></td>
</tr>
<tr>
<td>SSI, n (%)</td>
<td>2 (1.7)</td>
<td>0 (0)</td>
<td>0.999</td>
</tr>
<tr>
<td>AMI postoperative, n (%)</td>
<td>1 (0.9)</td>
<td>1 (2.9)</td>
<td>0.41</td>
</tr>
<tr>
<td>Hemodynamic instability, n (%)</td>
<td>8 (7.0)</td>
<td>9 (25.7)</td>
<td><strong>0.005</strong></td>
</tr>
<tr>
<td>Noradrenalin dose (mg)</td>
<td>2.25 (0.94–5.58)</td>
<td>5.76 (2.37–18.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Rethoracotomy, n (%)</td>
<td>5 (4.3)</td>
<td>3 (8.6)</td>
<td>0.39</td>
</tr>
<tr>
<td>Respiratory failure, n (%)</td>
<td>5 (4.3)</td>
<td>4 (11.4)</td>
<td>0.21</td>
</tr>
<tr>
<td>Transfusions, n (%)</td>
<td>35 (30.4)</td>
<td>22 (62.9)</td>
<td><strong>0.001</strong></td>
</tr>
<tr>
<td>Arrhythmia, n (%)</td>
<td>33 (28.7)</td>
<td>15 (42.9)</td>
<td>0.14</td>
</tr>
<tr>
<td>Delirium, n (%)</td>
<td>6 (5.2)</td>
<td>2 (5.7)</td>
<td>0.999</td>
</tr>
</tbody>
</table>

**Notes:** Data is presented as median (IQR25, IQR75). The bold values are statistically significant.

**Abbreviations:** AKI, acute kidney injury; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; ICD, implantable cardioverter defibrillator; ICU, intensive care unit; SSI, surgical site infection; TIA, transient ischemic attack.
and were also at high risk of in-hospital death (14.3% vs 0%, \( P=0.001 \)).

Preoperative SCr levels did not differ between patients who developed AKI compared with patients who did not (AKI: 1.00 [0.78–1.23] vs no-AKI: 0.90 [0.75–1.02] mg/dL; \( P=0.535 \); Table 2, Figure 1). Neither preoperative serum NGAL nor HO-1 levels differed between patients who subsequently developed AKI and those who did not (Table 2, Figures 2 and 3). Both markers were higher at ICU arrival as compared to baseline (\( P<0.001 \) for NGAL and HO-1) (Table 2, Figures 2 and 3). NGAL levels were significantly higher in patients who developed AKI within 48 hours (960 [614–1,262] pg/mL vs 600 [461–783] pg/mL, \( P<0.001 \)), while HO-1 levels did not differ (\( P=0.88 \)) at this time point (Table 2, Figures 2 and 3). In patients developing AKI, an additional increase of serum HO-1 levels 24 hours after surgery was observed, whereas in patients who subsequently did not develop AKI, serum HO-1 levels decreased (AKI: 12.75 [8.69–34.35] ng/mL vs no-AKI: 8.30 [4.13–15.60] ng/mL, \( P=0.031 \); Table 2 and Figures 2 and 3). In total, 45 patients (30%) developed AKI within the first 7 days after surgery and three patients required renal replacement therapy (Table 3). The severity of AKI is described in Table 3.

The results of univariate and multivariate logistic regression analyses are presented in Table 4. We analyzed the relationship of clinical relevant variables (age, EuroScore II, hypertension, diabetes, chronic obstructive pulmonary disease, peripheral artery disease, stroke in medical history, CPB time, deep hypothermic circulatory arrest, mechanical ventilation time, noradrenalin dose, resuscitation, hemodynamic instability, rethoracotomy and transfusions) and serum HO-1 levels with AKI. We found an independent relationship of serum HO-1 levels 24 hours after surgery with the development of AKI (\( P=0.043 \), OR 1.053, 95% CI: 1.002–1.107).

CPB time of all patients was associated with HO-1 levels (\( P=0.046 \), correlation coefficient=0.236) but not with HO-1 levels at 24 hours after surgery (\( P=0.219 \)). Furthermore, HO-1 levels at 24 hours after surgery in patients with AKI were associated with EuroScore II (\( P=0.048 \), correlation coefficient=0.181). Using ROC analyses, we provided a comparison of AUC between creatinine, NGAL postoperatively and HO-1 at 24 hours after surgery (Figure 4). Data are summarized in Table 5. By contrast, diagnostic accuracy for HO-1 at 24 hours after cardiac surgery was more reliable with a sensitivity of 75% and specificity of 85.8% for predicting AKI stage 2/3 after 48 hours (AUC 0.802, SE=0.102, 95% CI: 0.602–1.000, \( P=0.004 \); Figure 5).

### Discussion

In the present study, we investigated data from a prospective cohort study of 150 adult cardiac surgical patients. Our results indicate that HO-1 kinetics differ in patients developing AKI within 48 hours from those who do not. All patients – independent from subsequent incidence of AKI – showed an HO-1 increase immediately after the operation. While AKI patients showed a second burst 24 hours after surgery, HO-1 levels in patients without AKI decreased almost to baseline values. In multivariate analyses, HO-1 levels at 24 hours after surgery remained associated with AKI within 48 hours. HO-1 showed a stronger association with higher stages of AKI (stages 2 and 3) compared with the AKI stage 1 in the measurement 24 hours after the surgery. Further investigations showed that NGAL concentrations increased early after surgery and were associated with the incidence of AKI within 48 hours as well.

AKI, as defined by the most recent guidelines, has a very strict definition as a rise in SCr of \( \geq 0.3 \) mg/dL within 48 hours.\(^{11} \) Although a slight increase of SCr within 48 hours might not get noticed by the treating physicians in absence of a significant change of urine production, AKI stage 1 impacts the prognosis of a patient.\(^{6,8,9,23–25} \) Not only regarding an increased in-hospital mortality – as also confirmed in our cohort – but also the long-term prognosis of the

### Table 2 Serum creatinine levels preoperatively, 6, 24 and 48 hours postoperatively; plasma NGAL levels preoperatively and at arrival in ICU, plasma HO-1 levels preoperatively, at arrival in ICU and 24 hours postoperatively according to AKI 24 hours postoperatively

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>No AKI</th>
<th>AKI</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine preoperative ( (\text{mg/dL}) )</td>
<td>0.92 (0.76–1.04)</td>
<td>0.90 (0.75–1.02)</td>
<td>1.00 (0.78–1.23)</td>
<td>0.535</td>
</tr>
<tr>
<td>Creatinine 6 h ( (\text{mg/dL}) )</td>
<td>1.01 (0.83–1.04)</td>
<td>0.95 (0.78–1.11)</td>
<td>1.21 (1.09–1.50)</td>
<td>( 0.001 )</td>
</tr>
<tr>
<td>Creatinine 24 h ( (\text{mg/dL}) )</td>
<td>0.99 (0.81–1.23)</td>
<td>0.90 (0.75–1.04)</td>
<td>1.37 (1.20–1.78)</td>
<td>( &lt;0.001 )</td>
</tr>
<tr>
<td>Creatinine 48 h ( (\text{mg/dL}) )</td>
<td>0.97 (0.83–1.27)</td>
<td>0.89 (0.77–1.07)</td>
<td>1.68 (1.32–2.06)</td>
<td>( &lt;0.001 )</td>
</tr>
<tr>
<td>NGAL preoperative ( (\text{pg/mL}) )</td>
<td>352 (278–466)</td>
<td>336 (271–468)</td>
<td>360 (304–616)</td>
<td>0.80</td>
</tr>
<tr>
<td>NGAL ICU ( (\text{pg/mL}) )</td>
<td>628 (490–828)</td>
<td>600 (461–783)</td>
<td>960 (614–1262)</td>
<td>( &lt;0.001 )</td>
</tr>
<tr>
<td>HO-1 preoperative ( (\text{ng/mL}) )</td>
<td>7.34 (4.63–9.66)</td>
<td>6.98 (4.44–9.01)</td>
<td>6.29 (4.48–10.88)</td>
<td>0.83</td>
</tr>
<tr>
<td>HO-1 ICU ( (\text{ng/mL}) )</td>
<td>12.81 (8.81–19.59)</td>
<td>12.91 (8.73–19.54)</td>
<td>11.65 (9.95–21.49)</td>
<td>0.88</td>
</tr>
<tr>
<td>HO-1 24 h ( (\text{ng/mL}) )</td>
<td>9.71 (4.49–16.75)</td>
<td>8.30 (4.13–15.60)</td>
<td>12.75 (8.69–34.35)</td>
<td>( 0.031 )</td>
</tr>
</tbody>
</table>

Notes: Data is presented as median (IQR).\( 25,75 \). The bold values are statistically significant.

Abbreviations: AKI, acute kidney injury; HO-1, heme oxygenase 1; ICU, intensive care unit; NGAL, neutrophil gelatinase-associated lipocalin.
Figure 1 Creatinine levels preoperatively, at arrival in ICU, and 24 and 48 hours postoperatively for patients with and without AKI occurring within 48 hours postoperatively. 
Notes: 0 refers to no AKI in 48 hours after surgery and 1 refers to AKI 48 hours after surgery. The circles and stars are markers in our statistics software SPSS. The circles represent “out” values and stars represent “far out” values, based on interquartile range.
Abbreviations: AKI, acute kidney injury; AKI_48, acute kidney injury 48 hours after cardiac surgery; ICU, intensive care unit.

Figure 2 Plasma NGAL levels preoperatively and at arrival in ICU for patients with and without AKI occurring within 48 hours after cardiac surgery. 
Notes: 0 refers to no AKI in 48 hours after surgery and 1 refers to AKI 48 hours after surgery. The circles and stars are markers in our statistics software SPSS. The circles represent “out” values and stars represent “far out” values, based on interquartile range.
Abbreviations: AKI, acute kidney injury; AKI_48, acute kidney injury 48 hours after cardiac surgery; ICU, intensive care unit; NGAL, neutrophil gelatinase-associated lipocalin.

patients suffering from AKI demonstrated a higher rate in re-hospitalization, mortality and heart failure.6,8,9,23–25

HO-1 is upregulated in proximal tubular cells in response to oxidative stress and has protective anti-inflammatory and anti-oxidant effects.14 In rodent models, it has been associated with AKI.15 In cardiac surgery patients, it was associated with AKI after surgery in a very small sample of 74 patients,18 which was a substudy of a clinical trial using ACE inhibitors to prevent inflammatory reactions after cardiac surgery. ACE inhibitors have been described to increase HO-1 expression and might be a bias in the prior study.26 Although in both studies the measurements were performed at the same time points,
the course of HO-1 levels differed. While we observed one burst of HO-1 post-CPB, the earlier cohort showed a decrease in HO-1. Furthermore, we showed a decrease of HO-1 in patients without AKI, which was not shown in the first study.

In our cohort, elevation of HO-1 serum concentrations after CPB was positively associated with the CPB time. The ischemia–reperfusion stress of the cross-clamping and diastolic arrest represent an intensive oxidative stress trig-gering HO-1 production in different tissues.\(^{21,27,28}\) CPB time is a strong surrogate marker for the surgical complexity of the procedure itself and a complicated course during the operation.\(^{22}\) The longer a patient remains on CPB, the more oxidative stress is generated – not only in the myocardium but also in other sensitive tissues of the organism.\(^{21,22,28,29}\) Still the HO-1 elevation 24 hours after the surgery is a specific signal of renal stress. The first HO-1 induction does not differ between patients with or without AKI within the next 48 hours. Thus, we assume that the renal stress caused by the CPB might not be the only cause for AKI in our cohort. Patients with prolonged CPB times tend to have higher incidences of cardiogenic shock, anemia, bleeding, arrhythmia and pulmonary complications – all possible triggers of AKI for themselves.\(^{22,29–32}\) Our results might suggest that not the direct oxidative stress on the kidneys due to CPB is the causative for AKI, but the secondary upcoming complications and consequences of a long CPB duration.\(^{30,32}\) HO-1 levels 24 hours after surgery are not any longer associated with the CPB time but with the incidence of AKI. This second burst of HO-1 suggests that renal stress leading to AKI might be caused by, eg, inappropriate fluid management, diuretic treatment, appearance of cardiac shock or cardiac arrhythmias. Our results suggest that the time after surgery might be crucial for the development of AKI. Therefore, attention and targeted interventions to prevent AKI should be favorable during the postoperative phase, as already shown in literature.\(^{36}\)

HO-1 measurements 24 hours after surgery were associated with the EuroScore II. EuroScore II is a risk score for cardiovascular surgery taking comorbidities, demography and other factors into consideration and providing a good sum up of all relevant operative risk factors.\(^{30}\) Thus, our results suggest that the renal oxidative stress might be caused or
influenced by the comorbidities of the patient, as described previously in recent literature\textsuperscript{34,35,37,38}
\par
Being a rather late marker after cardiac surgery, HO-1 seems to be not helpful in clinical routine for early diagnostic issues after cardiac surgery compared to other biomarkers. Concurring with the literature we observed a statistically significant difference in HO-1 between AKI and no-AKI patients 24 hours after surgery.\textsuperscript{18} However, NGAL serum concentrations differed between the groups already after the CPB in our cohort, also according with the literature.\textsuperscript{39,41} But even NGAL does not provide an advantage over SCr to be of predictive value. Biomarkers for detection of acute kidney

\begin{table}[h]
\centering
\caption{Determinants of AKI development within 48 hours after cardiac surgery (unadjusted and adjusted logistic regression)}
\begin{tabular}{lllll}
\hline
Variables & Unadjusted (univariate analysis) P-value & Odds ratio (95\% CI) & Adjusted (multivariate analysis) P-value & Odds ratio (95\% CI) \\
\hline
Age & 0.013 & 1.054 (1.011–1.099) & 0.033 & 1.058 (1.005–1.114) \\
EuroScore II & 0.140 & 1.080 (0.975–1.196) & 0.031 & 1.012 (1.001–1.023) \\
Hypertension & 0.217 & 2.044 (0.657–6.354) & 0.006 & 1.071 (1.020–1.124) \\
Diabetes & 0.738 & 1.333 (0.247–7.192) & & \\
COPD & 0.680 & 0.841 (0.370–1.914) & & \\
Peripheral artery disease & 0.011 & 0.220 (0.069–0.707) & & \\
Stroke & 0.013 & 1.010 (1.002–1.019) & & \\
CPB time & & & & \\
DHCA & 0.749 & 0.798 (0.200–3.184) & 0.004 & 1.110 (1.034–1.192) \\
Mechanical ventilation time & 0.006 & 1.071 (1.020–1.124) & 0.043 & 1.053 (1.002–1.107) \\
Noradrenalin dose & 0.001 & 1.090 (1.038–1.144) & & \\
HO-1 24 h ng/mL & <0.001 & 1.075 (1.035–1.117) & & \\
Resuscitation & 0.382 & 0.442 (0.071–2.757) & & \\
Hemodynamic instability & 0.004 & 0.216 (0.076–0.614) & & \\
Rethoracotomy & 0.339 & 0.485 (0.110–1.940) & & \\
Transfusions & 0.001 & 0.269 (0.122–0.594) & & \\
\hline
\end{tabular}
\textbf{Note:} The bold values are statistically significant.
\textbf{Abbreviations:} AKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; HO-1, heme oxygenase 1.
\end{table}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{ROC_curves.png}
\caption{ROC curves showing the interaction between creatinine levels at 6, 24, and 48 hours postop, NGAL immediately postop, and serum HO-1 levels 24 hours postop, for the prediction of any stages of AKI occurring within 48 hours postoperatively.}
\textbf{Note:} Diagonal segments are produced by ties.
\textbf{Abbreviations:} AKI, acute kidney injury; crea, creatinine; HO-1, heme oxygenase 1; NGAL, neutrophil gelatinase-associated lipocalin; postop, postoperative; ROC, receiver operating characteristic.
\end{figure}
injury induced after the tubular damage has occurred are unsuitable for early diagnostics because the treatment options after the renal damage are limited.41 Some biomarkers, such as tissue inhibitor of metalloproteinase two and insulin-like growth factor binding protein 7 ([TIMP-2]*[IGFBP7]), seem to provide some significant timing advantage.41–44 In our cohort, HO-1 carried some benefits over other markers. In contrast to NGAL, HO-1 was very specific for AKI.40,45 The HO-1 serum concentrations 24 hours after surgery had a specificity of over 91% for AKI. By contrast, NGAL concentrations in serum increase due to oxidative stress in other organs as well and are less specific for AKI.41 On the other hand, this association might be caused by the high cutoff level, and HO-1 elevation could be caused by general oxidative stress. ([TIMP-2]*[IGFBP7]) has a very high sensitivity of up to 90% in literature but has a rather low specificity (about 60%).44,46 With its high specificity, HO-1 might gather additional information about AKI especially in combination with other markers.

After cardiac surgery, serum NGAL levels have been shown to increase early within 2 hours and have already been proven to be predictive of the duration and severity of AKI after cardiac surgery.39 Recently, NGAL has been investigated extensively and appeared to be one of the most promising early biomarkers after renal injury.40 A meta-analysis including 19 studies with 2,500 patients was performed to estimate the diagnostic and therapeutic accuracy of NGAL in AKI.33 In conclusion, NGAL was found to be a useful early predictor of AKI with prognostic value for clinical end points. Unfortunately, substantial extrarenal NGAL generation in response to systemic stress can increase NGAL level in the absence of AKI,39 which partly limits its value in diagnostic accuracy.

Table 5  ROC dates summarized for creatinine, NGAL postoperatively and serum HO-1 levels after 24 hours postoperatively for the prediction of AKI any stages in 48 hours

<table>
<thead>
<tr>
<th>Variables</th>
<th>AUC</th>
<th>P-value</th>
<th>SE</th>
<th>95% CI</th>
<th>Cutoff</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine 6 h mg/dL</td>
<td>0.824</td>
<td>&lt;0.001</td>
<td>0.054</td>
<td>0.719–0.929</td>
<td>1.00</td>
<td>94.4</td>
<td>63.3</td>
<td>40.3</td>
<td>94.4</td>
</tr>
<tr>
<td>Creatinine 24 h mg/dL</td>
<td>0.857</td>
<td>&lt;0.001</td>
<td>0.050</td>
<td>0.759–0.955</td>
<td>1.13</td>
<td>88.9</td>
<td>83.5</td>
<td>53.8</td>
<td>92.8</td>
</tr>
<tr>
<td>Creatinine 48 h mg/dL</td>
<td>0.893</td>
<td>&lt;0.001</td>
<td>0.048</td>
<td>0.798–0.987</td>
<td>1.22</td>
<td>88.9</td>
<td>87.3</td>
<td>68.2</td>
<td>95.3</td>
</tr>
<tr>
<td>NGAL postop pg/mL</td>
<td>0.762</td>
<td>0.001</td>
<td>0.070</td>
<td>0.626–0.899</td>
<td>810</td>
<td>66.7</td>
<td>81</td>
<td>44.8</td>
<td>92</td>
</tr>
<tr>
<td>HO-1 24 h ng/mL</td>
<td>0.665</td>
<td>0.030</td>
<td>0.080</td>
<td>0.508–0.821</td>
<td>23.66</td>
<td>38.9</td>
<td>93.7</td>
<td>63.2</td>
<td>82.6</td>
</tr>
</tbody>
</table>

Note: The bold values are statistically significant.

Abbreviations: AUC, area under the curve; AKI, acute kidney injury; HO-1, heme oxygenase 1; NGAL, neutrophil gelatinase-associated lipocalin; NPV, negative predictive value; postop, postoperative; PPV, positive predictive value; ROC, receiver operating characteristic.

Figure 5  ROC curves for serum HO-1 levels 24 hours postoperatively for the prediction of any stage of AKI (A) and stage 2 or 3 AKI (B) occurring within 48 hours postoperatively.

Abbreviations: AKI, acute kidney injury; HO-1, heme oxygenase 1; ROC, receiver operating characteristic.
other limitations of the present study. A limited sample size prevents extensive multivariate adjustments, but this study still investigated the largest prospective cohort on HO-1 in cardiac surgery. Additionally, with the predefined exclusion criteria in our cohort, we could not study patients with pre-existing advanced CKD and cannot comment or extrapolate on patients with CKD grade G4 or higher according to the KDIGO classification. Further information could be gathered by measuring HO-1 in urine as well, but this was not depicted in the study protocol. Finally, there is a potential treatment bias, because our protocol did not involve predefined approaches of treatment in case of postoperative AKI.

**Conclusion**

HO-1 measurements 24 hours after cardiac surgery are associated with AKI within 48 hours after surgery. Early measurements at ICU admission do not show any association with AKI. Further research on this marker in larger cohorts is important to characterize the entire value and determinants of the HO-1 kinetics. Clinical usefulness of this marker has yet to be investigated.

**Acknowledgment**

This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding program Open Access Publishing.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**